Efficacy of Naproxen/Fexofenadine (SJP-003) in the Prevention of Side Effects of Influenza Vaccination: Four Case Studies

Publication date

2022-10

Authors

Kiani, Pantea
Dahl, Thomas A
Iversen, Jacqueline M
Scholey, Andrew
Verster, J.C.ORCID 0000-0002-6455-2096ISNI 0000000076939752

Editors

Advisors

Supervisors

Document Type

Article
Open Access logo

License

cc_by

Abstract

The influenza virus is associated with sickness, and in particular among vulnerable populations such as elderly and those with underlying disease with hospitalization and increased mortality rates. Vaccination is an effective way to prevent infection with influenza. However, undesirable side effects of the vaccination are commonly experienced, and comprise one of the primary reasons for a substantial group of individuals to refrain from vaccination. An effective treatment against vaccination side effects could increase the overall willingness to vaccinate against influenza. Here, four cases are presented that self-administered SJP-003 (a combination of 220 mg naproxen sodium, directly followed by a single oral dose of 60 mg fexofenadine HCL), 2 h before and 10 h after influenza vaccination. No flu-like symptoms and pain at the injection site were reported. These observations warrant further investigation of SJP-003 in double-blind, placebo-controlled clinical trials.

Keywords

SDG 3 - Good Health and Well-being

Citation

Kiani, P, Dahl, T A, Iversen, J M, Scholey, A & Verster, J C 2022, 'Efficacy of Naproxen/Fexofenadine (SJP-003) in the Prevention of Side Effects of Influenza Vaccination : Four Case Studies', Clinics and Practice, vol. 12, no. 5, pp. 734-737. https://doi.org/10.3390/clinpract12050076